Clinical efficacy and safety of statins in managing cardiovascular risk
- PMID: 18561510
- PMCID: PMC2496987
- DOI: 10.2147/vhrm.s1653
Clinical efficacy and safety of statins in managing cardiovascular risk
Abstract
Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of 'lower is better' has corresponded with a more is better' approach to statin-based therapy. This review provides a detailed understanding of the clinical efficacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin.
Similar articles
-
An update on the benefits and risks of rosuvastatin therapy.Postgrad Med. 2014 Mar;126(2):7-17. doi: 10.3810/pgm.2014.03.2736. Postgrad Med. 2014. PMID: 24685964 Review.
-
Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.Expert Opin Pharmacother. 2005 Sep;6(11):1897-910. doi: 10.1517/14656566.6.11.1897. Expert Opin Pharmacother. 2005. PMID: 16144509 Review.
-
[Lipid lowering by rosuvastatin: how do statins differ?].Dtsch Med Wochenschr. 2015 Mar;140(5):313. doi: 10.1055/s-0041-100713. Epub 2015 Mar 3. Dtsch Med Wochenschr. 2015. PMID: 25734669 Review. German. No abstract available.
-
Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study.Vasc Health Risk Manag. 2008;4(6):1407-16. doi: 10.2147/vhrm.s4151. Vasc Health Risk Manag. 2008. PMID: 19337553 Free PMC article. Clinical Trial.
-
An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):287-304. doi: 10.1517/17425255.4.3.287. Expert Opin Drug Metab Toxicol. 2008. PMID: 18363544 Review.
Cited by
-
Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria.BMC Health Serv Res. 2019 Nov 27;19(1):902. doi: 10.1186/s12913-019-4736-3. BMC Health Serv Res. 2019. PMID: 31775736 Free PMC article.
-
Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?Br J Pharmacol. 2012 Jan;165(2):373-9. doi: 10.1111/j.1476-5381.2011.01597.x. Br J Pharmacol. 2012. PMID: 21790534 Free PMC article. Review.
-
Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway.Drug Des Devel Ther. 2015 Jun 23;9:3217-29. doi: 10.2147/DDDT.S86431. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26150695 Free PMC article.
-
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.Leukemia. 2021 Mar;35(3):796-808. doi: 10.1038/s41375-020-0962-2. Epub 2020 Jul 14. Leukemia. 2021. PMID: 32665698 Free PMC article.
-
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.Vasc Health Risk Manag. 2017 Feb 16;13:29-41. doi: 10.2147/VHRM.S95044. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28243111 Free PMC article. Review.
References
-
- Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111:3051–7. - PubMed
-
- Alsheikh-Ali A, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409–18. - PubMed
-
- Arca Marcello. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs. 2007;67:43–54. - PubMed
-
- Armitage J. The safety of statins in clinical practice. Lancet. 2007 Jun 6; Epub ahead of print. - PubMed
-
- [ALLHAT] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998–3007. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials